Amitriptyline Revitalizes ICB Response Via Dually Inhibiting Kyn/Indole and 5-HT Pathways of Tryptophan Metabolism in Ovarian Cancer

Overview

Journal iScience

Publisher Cell Press

Date 2025 Jan 6

PMID 39759009

Authors

Junyang Li

Bingjie Mei

Lu Feng

Xiaoxin Wang

Dengfeng Wang

Jianming Huang

Guonan Zhang

Affiliations

Soon will be listed here.

Abstract

Reprogramming tryptophan metabolism (TRP) may be able to overcome immunosuppression and restore the immune checkpoint blockade (ICB) response in patients with epithelial ovarian cancer (EOC) resistant to ICB therapy because TRP metabolism is involved in the kynurenine/indole and serotonin pathways of tryptophan metabolism. Herein, employing amitriptyline (AMI), an antagonist of TLR4 and serotonin transporter (SERT), we revealed that AMI remodels the immunological landscape of EOC. In particular, AMI lowered the expression of IDO1, IL-4I1, and PD-L1, the quantity of KYN and indoles, and the level of immunosuppressive immune cells MDSC, Tregs, and CD8CD39+/PD-1+ T cell. AMI boosted the killing potential of anti-PD-1-directed CD8+T cells and worked in concert with PD-1 inhibitors to suppress tumor growth and to prolong the survival of EOC-bearing mice. This work highlights AMI as an effective regulator of ICB response by manipulating EOC cell TRP metabolism, indicating it could be a potential strategy for improving EOC ICB therapy.

References

Badawy A . Tryptophan metabolism and disposition in cancer biology and immunotherapy. Biosci Rep. 2022; 42(11). PMC: 9653095. DOI: 10.1042/BSR20221682. View

Matulonis U, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I . Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019; 30(7):1080-1087. DOI: 10.1093/annonc/mdz135. View

Lemos H, Huang L, Prendergast G, Mellor A . Immune control by amino acid catabolism during tumorigenesis and therapy. Nat Rev Cancer. 2019; 19(3):162-175. DOI: 10.1038/s41568-019-0106-z. View

Rodriguez G, Galpin K, McCloskey C, Vanderhyden B . The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy. Cancers (Basel). 2018; 10(8). PMC: 6116043. DOI: 10.3390/cancers10080242. View

Matulonis U, Sood A, Fallowfield L, Howitt B, Sehouli J, Karlan B . Ovarian cancer. Nat Rev Dis Primers. 2016; 2:16061. PMC: 7290868. DOI: 10.1038/nrdp.2016.61. View

Bortolato B, Hyphantis T, Valpione S, Perini G, Maes M, Morris G . Depression in cancer: The many biobehavioral pathways driving tumor progression. Cancer Treat Rev. 2016; 52:58-70. DOI: 10.1016/j.ctrv.2016.11.004. View

Wang K, Li Y, Jiang Y, Dai C, Patankar M, Song J . An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells. Cancer Lett. 2013; 340(1):63-71. PMC: 3781955. DOI: 10.1016/j.canlet.2013.06.026. View

DePeaux K, Delgoffe G . Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021; 21(12):785-797. PMC: 8553800. DOI: 10.1038/s41577-021-00541-y. View

Rudorfer M, Manji H, Potter W . Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf. 1994; 10(1):18-46. DOI: 10.2165/00002018-199410010-00003. View

10.

Li Y, Hu N, Yang D, Oxenkrug G, Yang Q . Regulating the balance between the kynurenine and serotonin pathways of tryptophan metabolism. FEBS J. 2017; 284(6):948-966. DOI: 10.1111/febs.14026. View

11.

Trikha P, Lee D . The role of AhR in transcriptional regulation of immune cell development and function. Biochim Biophys Acta Rev Cancer. 2019; 1873(1):188335. DOI: 10.1016/j.bbcan.2019.188335. View

12.

Tassi E, Bergamini A, Wignall J, SantAngelo M, Brunetto E, Balestrieri C . Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells. Front Immunol. 2023; 14:1212444. PMC: 10585363. DOI: 10.3389/fimmu.2023.1212444. View

13.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

14.

Yost K, Satpathy A, Wells D, Qi Y, Wang C, Kageyama R . Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019; 25(8):1251-1259. PMC: 6689255. DOI: 10.1038/s41591-019-0522-3. View

15.

Sperner-Unterweger B, Neurauter G, Klieber M, Kurz K, Meraner V, Zeimet A . Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers. Immunobiology. 2010; 216(3):296-301. DOI: 10.1016/j.imbio.2010.07.010. View

16.

Roman D, Walline C, Rodriguez G, Barker E . Interactions of antidepressants with the serotonin transporter: a contemporary molecular analysis. Eur J Pharmacol. 2003; 479(1-3):53-63. DOI: 10.1016/j.ejphar.2003.08.056. View

17.

Vindevogel E, Baert T, Van Hoylandt A, Verbist G, Velde G, Garg A . The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer. Anticancer Res. 2016; 36(11):5781-5792. DOI: 10.21873/anticanres.11162. View

18.

Hao X, Shen Y, Chen N, Zhang W, Valverde E, Wu L . Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal. Cell Stem Cell. 2023; 30(5):648-664.e8. PMC: 10165729. DOI: 10.1016/j.stem.2023.04.005. View

19.

Odunsi K, Qian F, Lugade A, Yu H, Geller M, Fling S . Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022; 14(636):eabg8402. PMC: 9311231. DOI: 10.1126/scitranslmed.abg8402. View

20.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View